Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $7.73.

  • United Therapeutics' EPS (Basic) rose 1154.4% to $7.73 in Q3 2025 from the same period last year, while for Sep 2025 it was $28.48, marking a year-over-year increase of 1715.34%. This contributed to the annual value of $26.44 for FY2024, which is 2566.67% up from last year.
  • According to the latest figures from Q3 2025, United Therapeutics' EPS (Basic) is $7.73, which was up 1154.4% from $6.86 recorded in Q2 2025.
  • Over the past 5 years, United Therapeutics' EPS (Basic) peaked at $7.73 during Q3 2025, and registered a low of $0.63 during Q1 2021.
  • For the 5-year period, United Therapeutics' EPS (Basic) averaged around $5.04, with its median value being $5.31 (2022).
  • Its EPS (Basic) has fluctuated over the past 5 years, first plummeted by 7993.63% in 2021, then skyrocketed by 74285.71% in 2022.
  • Quarter analysis of 5 years shows United Therapeutics' EPS (Basic) stood at $2.48 in 2021, then grew by 14.52% to $2.84 in 2022, then soared by 61.97% to $4.6 in 2023, then soared by 44.91% to $6.67 in 2024, then grew by 15.96% to $7.73 in 2025.
  • Its EPS (Basic) stands at $7.73 for Q3 2025, versus $6.86 for Q2 2025 and $7.18 for Q1 2025.